Alnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of ($1.22), $0.25 better than the analyst estimate of ($1.47). Revenue for the quarter came in at $21.9 million versus the consensus estimate of $30.15 million.

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.